Sparks commentary - Elicera Therapeutics

Healthcare

Sparks - Elicera Therapeutics

More on this equity
Elicera (ST: ELIC) reports positive CAR-T data in Phase I/IIa CARMA study
Published by Arron Aatkar, PhD

Elicera Therapeutics has announced preliminary principal investigator-assessed outcomes from the first patient cohort in the ongoing Phase I/IIa CARMA trial. CARMA is assessing the company’s proprietary iTANK-armed CAR T-cell therapy, ELC-301, in patients with relapsed or refractory B-cell lymphoma. The first dose cohort included three patients treated with the lowest dose, equivalent to one-tenth of the planned maximum dose. Encouragingly, two of three treated patients show no active lymphoma on specialised scans, achieving a complete metabolic response.

The Phase I/IIa CARMA trial continues to enrol patients at escalating dose levels to further evaluate safety, tolerability and preliminary efficacy. The second cohort has already been initiated, with two patients treated so far at a dose level three times higher than that of the first cohort.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.